BMS-P5

• Description :

  BMS-P5 is a selective and orally active peptidylarginine deiminase 4 (PAD4) inhibitor with an IC50 of 98 nM. BMS-P5 shows selective for PAD4 over PAD1, PAD2, and PAD3. BMS-P5 blocks multiple myeloma (MM) -induced neutrophil extracellular trap (NET) formation and delays progression of MM in a syngeneic mouse model[1].

• UNSPSC :

  12352005

• Target :

  Protein Arginine Deiminase

• Type :

  Reference compound

• Related Pathways :

  Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bms-p5.html

• Purity :

  99.23

• Solubility :

  DMSO : 35 mg/mL (ultrasonic)

• Smiles :

  O=C(N1[C@@H](C)CC[C@@H](N)C1)C2=CC(OC)=C3C(N=C(C4=CC5=CC=CN=C5N4CC6CC6)N3C)=C2.[H]Cl

• Molecular Formula :

  C27H33ClN6O2

• Molecular Weight :

  509.04

• References & Citations :

  [1]Marina Li, et al. A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Mol Cancer Ther. 2020 Jul;19 (7) :1530-1538.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1549811-36-0]